As criticism of pharmacy benefit managers intensifies, CVS Caremark (CVS) plans to roll out a new prescription-drug pricing model next month for health plans that the company maintains will “simplify” costs and simultaneously add a dose of transparency to a highly opaque system.

In short, the PBM will offer so-called guaranteed net pricing for average prescription claims, whether medicines are purchased by mail or from retail or specialty pharmacies. CVS says it will pass through all rebates and administrative fees to its clients while assuming responsibility for manufacturer price hikes and shifts in the mix of brand and generic drugs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • The silverscript allure with pass thru rebates more than makes up their margin with 10X pricing on generics. One customer with 9 generics averaged $128 more per rx than the plain silverscript plan.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy